Table 1

Expression of MMP-2 in stromal fibroblasts and tumor cells in non-small cell lung cancer

Expression of MMP-2
Stromal fibroblastsTumor cells
WeakStrongPWeakStrongP
All Patients86 (39.4%)132 (60.6%)164 (75.2%)54 (24.8%)
Age (mean in y)61.563.10.22863.559.50.006
 Lower*45 (41.7%)63 (58.3%)0.58075 (69.4%)33 (30.6%)0.060
 Higher*41 (37.3%)69 (62.7%)89 (80.9%)21 (19.1%)
Gender
 Male58 (36.9%)99 (63.1%)0.280120 (76.4%)37 (23.6%)0.600
 Female28 (45.9%)33 (54.1%)44 (75.2%)17 (27.9%)
Performance status
 079 (41.4%)112 (58.6%)144 (75.4%)47 (24.6%)
 17 (28.0%)18 (72.0%)0.22719 (76.0%)6 (24.0%)0.707
 20 (0.0%)2 (100%)1 (50.0%)1 (50.0%)
Histologic type
 Squamous cell carcinoma21 (27.3%)56 (72.7%)0.01667 (87.0%)10 (13.0%)0.004
 Adenocarcinoma55 (45.1%)67 (54.9%)84 (68.9%)38 (31.1%)
 Large-cell cacinoma4 (36.4%)7 (63.6%)8 (72.7%)3 (27.3%)
 Others6 (75.0%)2 (25.0%)5 (62.5%)3 (37.5%)
Tumor differentiation
 I53 (42.4%)72 (57.6%)91 (72.8%)34 (27.2%)
 II10 (41.7%)14 (58.3%)0.45321 (87.5%)3 (12.5%)0.311
 IIIA23 (33.3%)46 (66.7%)52 (75.4%)17 (24.6%)
  • NOTE. Each figure shows the number of patients, and the percentage is shown in parentheses.

  • * Lower, age < 64 years; Higher, age ≥ 64 years.

  • Comparison between squamous cell carcinoma and adenocarcinoma.